Demographic, clinical, and laboratory characteristics and outcomes of patients who ever received etravirine and/or darunavir - multi-country data abstraction
NCT ID NCT04194021
First seen Sep 09, 2026 · Last updated Sep 09, 2026
Summary
The objectives of this data collection activity are to: 1. Describe the baseline demographics, clinical and laboratory profile of patients who ever received darunavir (DRV) and/or etravirine (ETR), at the time of initiation on DRV and/or ETR; 2. Describe the clinical and laboratory profile of patients who ever received DRV and/or ETR every 6 months from the first data collection point through 2021; 3. Describe dynamics in HIV drug resistance mutations among patients who fail treatment on new regimens including DRV and/or ETR; 4. Describe demographics, clinical and laboratory profile of young adults who transition out of the donation program after the age of 25 years at 12 months after their transition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
871 people
The number who actually took part.
- Started
-
Jan 2019
- Finished
-
Dec 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients who ever received darunavir and/or etravirine before turning age 25 and residing in the following countries: Cameroon, Eswatini, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, Zimbabwe.
- Ages
-
Up to 25 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Ever received darunavir and/or etravirine. * Under age 25. * Residing in any of the following countries: Cameroon, Ethiopia, Eswatini, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe. Exclusion Criteria: * Above age 25. * Residing in a country not participating in the New Horizons Collaborative.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Elizabeth Glaser Pediatric AIDS Foundation/Cameroon
Yaoundé, Centre Region, Cameroon
-
Elizabeth Glaser Pediatric AIDS Foundation/Eswatini
Mbabane, Hhohho Region, Eswatini
-
Elizabeth Glaser Pediatric AIDS Foundation/Kenya
Nairobi, Kenya
-
Elizabeth Glaser Pediatric AIDS Foundation/Lesotho
Maseru, Lesotho
-
Elizabeth Glaser Pediatric AIDS Foundation/Uganda
Mbarara, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pill HIV prevention strategy outsmart the virus?
- Peer mentors may help women stay HIV-Free – trial tests new approach
- Can surveillance catch birth defects early in HIV-Affected pregnancies?
- Can a robot help stroke survivors with HIV walk again?
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Can a Father-Focused program curb HIV, substance abuse, and violence?